Proficient and cost-effective approaches for the prevention and treatment of venous thrombosis and thromboembolism

Drugs

Volumn 60, Issue 3, 2000, Pages 575-595

  Bick, Rodger L ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Dallas Helps   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ESTROGEN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; ORAL CONTRACEPTIVE AGENT; WARFARIN;

CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; INCIDENCE; LEG COMPRESSION; LENGTH OF STAY; LUNG EMBOLISM; META ANALYSIS; MORTALITY; PRACTICE GUIDELINE; PROTHROMBIN TIME; REVIEW; RISK ASSESSMENT; THROMBOEMBOLISM; UNITED STATES; VEIN THROMBOSIS;

EID: 0033781629     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200060030-00005     Document Type: Review

References (99)

1. Current status of thrombosis: A multidisciplinary medical issue and major American health problem: Beyond the year 2000
2. Syndromes of thrombosis and hyper-coagulability: Congenital and acquired causes of thrombosis
3. Deep vein thrombosis: Prevalence of etiologic factors and results of management in 100 consecutive patients
4. Incidence of venous thromboembolism in medical and surgical patients
5. Trends in the incidence of deep vein thrombosis and pulmonary embolism: A 25-year population-based study
6. The natural history of deep vein thrombosis
7. Blood protein defects associated with thrombosis: Laboratory assessment
8. Inherited thrombophilia: Pathogenesis, clinical syndromes and management
9. Sticky platelet syndrome: A common cause of unexplained venous and arterial thrombosis-results of prevalence and treatment outcome
10. Ten year's experience with the 'Sticky Platelet Syndrome'
11. The antiphospholipid thrombosis syndromes: A common multidisciplinary medical problem
12. Antiphospholipid thrombosis syndromes: Etiology, pathophysiology, diagnosis and management
13. Therapy for venous thrombosis: Guidelines for a competent and cost-effective approach
14. Prevalence of hereditary and acquired coagulation protein/platelet defects in patients with cerebral ischemic events
15. Syndromes of thrombosis and hypercoagulability: Congenital and acquired thrombophilias
16. Long-term outcomes of deep-vein thrombosis
17. The long-term clinical course of acute deep venous thrombosis
18. Dalteparin: A low molecular weight heparin
19. Ardeparin and danaparoid for prevention of deep vein thrombosis
20. International consensus recommendations: Summary statement and additional suggested guidelines
21. Conference on anti-thrombotic therapy
22. European Consensus Statement on the prevention of venous thromboembolism
23. Treatment of venous thrombosis and pulmonary embolism
24. Prevention of venous thromboembolism. International Consensus Statement (guideline according to scientific evidence)
25. Medicolegal implications of consensus statements
26. Prophylaxis of deep venous thrombosis and pulmonary embolus: Current recommendations
27. Pulmonary embolism as a cause of death: The changing mortality in hospitalized patients
28. Natural history of pulmonary embolism
29. Diagnosis of deep venous thrombosis and pulmonary emboism
30. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: The Worcester DVT study
31. Prevention of venous thromboembolism in general surgical patients: Results of meta-analysis
32. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin
33. Prevention of venous thromboembolism: International Consensus Statement
34. Prevention of thromboembolism European Consensus Statement
35. Underuse of venous thromboembolism prophylaxis for general surgery patients
36. Preventive and therapeutic approach to venous thromboembolism: Can death from pulmonary embolism be prevented?
37. Anticoagulant prophylaxis in surgical patients
38. Anticoagulant prophylaxis of thromboembolism in post-surgical patients
39. International Multicentre Trial: Prevention of fatal postoperative pulmonary embolism by low doses of heparin
40. Prevention in individual patient groups: General surgery
41. 'Delayed' prophylactic anticoagulation: A study of results and complications in 2,012 total hip arthroplasties
42. Anticoagulant prophylaxis, thromboembolism and mortality in elderly patients with hip fracture: A controlled clinical trial
43. Starting prophylaxis for venous thromboembolism postoperatively
44. Postoperative versus preoperative initiation of deep-vein thrombosis prophylaxis with a low molecular weight heparin (Nadroparin) in elective hip replacement
45. Diagnostic efficacy of impedance plethysmography for clinically suspected deep-vein thrombosis: A randomized trial
46. Heparin associated thrombocytopenia and other adverse effects of heparin therapy
47. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery: The Thrombo-prophylaxis Collaborative Group
48. Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial
49. Low-molecular-weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis
50. Low-molecular-weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis
51. Comparison of a low-molecular-weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery
52. A randomized double-blind study between a low-molecular-weight heparin Kabi 2165 and standard heparin in the prevention of deep-vein thrombosis in general surgery: A French multicentre trial
53. Prevention of peri-operative deep vein thrombosis in general surgery: A multi-centre double-blind study comparing two doses of logiparin and standard heparin
54. A comparative trial of a low molecular weight heparin (Enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery
55. Low molecular weight heparin started before surgery, as prophylaxis against deep vein thrombosis: 2500 versus 500 XaI units in 2070 patients
56. Prevention of deep vein thrombosis after major knee surgery: A randomized, double-blind trial comparing a low-molecular-weight heparin fragment (Enoxaparin) to placebo
57. Prevention of venous thromboembolism after knee arthroplasty - A randomized, double-blind trial comparing a low molecular weight heparin fragment (Enoxparin) to Warfarin
58. Efficacy and safety of Normiflow (a LMWH) compared to warfarin for prevention of venous thromboembolism following total knee replacement: A double-blind, dose-ranging study
59. Low molecular weight heparin in the prophylaxis of venous thrombosis: A meta-analysis
60. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma
61. Prevention of venous thrombosis with minidose warfarin after joint replacement
62. The effect of intermittently applied external pressure on the hemodynamics of the lower limb in man
63. Prevention of deep vein thrombosis in neurosurgical patients: A controlled, randomized trial of external pneumatic compression boots
64. The efficacy of pneumatic compression stockings in the prevention of pulmonary embolism after cardiac surgery
65. Effectiveness of intermittent pneumatic leg compression for preventing deep vein thrombosis after total hip replacement
66. Prevention of venous thromboembolism
67. The efficacy of graduated compression stockings in the prevention of deep vein thrombosis after major gynecological surgery
68. Effectiveness and safety of low molecular weight heparins (LMWH) in the prevention of venous thromboembolism
69. Treatment of deep venous thrombosis: Current recommendations
70. Calf deep vein thrombosis: A wolf in sheep's clothing
71. Deep vein thrombosis: Diagnosis and management
72. Thrombolytic therapy
73. Thrombolytic therapy: Agents, indications and laboratory monitoring
74. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis: A meta-analysis
75. Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis
76. Subcutaneous administration of heparin: A randomized comparison with intravenous administration of heparin to patients with deep-vein thrombosis
77. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal vein thrombosis
78. The importance of initial treatment on long-term outcomes of antithrombotic therapy
79. Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapy
80. Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism
81. A Collaborative European Multicentre Study: A randomized trail of subcutaneous low molecular weight heparin (CY216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis
82. A new treatment of deep venous thrombosis: Low molecular weight heparin fractions: Randomized study
83. Once-daily subcutaneous Dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis
84. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis
85. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home
86. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis
87. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis
88. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: A Polish multicenter trial
89. Low molecular weight heparin (Fragmin) once daily vs continuous infusion of standard heparin in the treatment of DVT
90. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis
91. Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the initial treatment proximal vein thrombosis
92. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism: The THESEE Study Group
93. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane review
94. The treatment of proximal vein thrombosis with subcutaneous low molecular weight heparin compared with continuous intravenous heparin: The Canadian-American Thrombosis Study Group
95. Low-molecular-weight heparin: An opportunity for home treatment of venous thrombosis
96. Assessment of out-patient treatment of deep-vein thrombosis with low-molecular-weight heparin
97. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolus with low-molecular-weight heparin: A comparison of self-injection with homecare injection